

meeting

Feb 2
SI

F-SPI-9AC
VCM/PVC Producers

VCM AND PVC PRODUCERS GROUP
STEERING COMMITTEE MEETING

SPI Conference Room
New York, New York

Wednesday, February 2, 1977
9:30 A.M.

Please hold February 2nd as a tentative date for a meeting of the VCM/PVC Producers Group Steering Committee. We feel that there will be sufficient activities to justify a meeting of the Steering Committee at this time. However, we will confirm the meeting and supply a specific agenda as this date approaches.

It has been suggested by the Chairman that we attempt to streamline our activities at this meeting. We would, therefore, like to limit attendance to one representative per company unless a second person would be required for proper coverage of your company's interest.

Very truly yours,

John R. Lawrence

John R. Lawrence
Technical Director

VCM AND PVC PRODUCERS GROUP
STEERING COMMITTEE

SPI Conference Room
New York, New York

Wednesday, February 2, 1977
11:00 A.M.

ACTION SUMMARY:

1. New bylaws in preparation for submission to full Producers Group.
2. Health Committee appointed.
3. EPA/EDF Suit Action
 - SPI will not seek a stay on present Standard.
 - SPI will file for an expedited review of Suit.
 - Counsel will attempt to sit in on negotiations.
4. Approved up to \$10,000 to counter New Jersey bill that would block vinyl chloride and polyvinyl chloride.
5. Media briefings to be resumed.
6. Nominating Committee to be appointed.
7. Meeting of full Producers Group to be held in Washington in mid April.

ATTENDEES:

Ed Ackerman, Diamond Shamrock, 1100 Superior Avenue, Cleveland, Ohio 44114
Gary H. Baise, Beveridge, Fairbanks & Diamond, One Farragut Square South, Washington, D.C.
John T. Barr, Air Products & Chemicals, Box 538, Allentown, Pa 18105
Dan S. Dixler, Keller & Heckman, 1150 17th Street, N.W. Washington, D.C. 20036
Robert Ferrante, Hill & Knowlton, 633 Third Avenue, New York, N. Y. 10017
Jerome H. Heckman, Keller & Heckman, 1150 17th Street, N.W. Washington, D.C. 20036
Harold Himmelman, Beveridge, Fairbanks & Diamond, One Farragut Square So. Wash. D.C.
John R. Lawrence, SPI, 355 Lexington Avenue, New York, N.Y. 10017
D. C. Nuechterlein, Dow Chemical USA, 2020 Dow Center, Midland, Michigan 48640
Frank X. Ritter, Tenneco Inc. Box 365, Piscataway, NJ 08854
Richard D. Savage, B. F. Goodrich Chemical Corp. 6100 Oak Tree Blvd. Cleveland, Ohio
Steven W. Schaefer, Diamond Shamrock, 1100 Superior Avenue, Cleveland, Ohio 44114
K. L. Spalding, Shell Chemical Co. One Shell Plaza, Houston, Texas 77001
Matt Swetonic, Hill & Knowlton, 633 Third Avenue, New York, N. Y. 10017
Todd C. Walker, Firestone Plastics Co. Box 699, Pottstown, Pa 19464

1. Acting Chairman Mr. Nuechterlein called on Messrs. Schaefer and Heckman to review the draft bylaws for the permanent Polyvinyl Chloride Safety Group. Mr. Heckman's draft included many of the concepts in Mr. Schaefer's original with some minor changes to include principles used with other SPI committees.

Mr. Nuechterlein suggested that a member of the Steering Committee be given overseeing responsibility for each of the standing subcommittees. He also suggested that all member companies be encouraged to actively participate in at least one of the standing subcommittees - not necessarily a bylaw item.

Subcommittees to be included in bylaws:

- | | |
|--------------------|---------------------------|
| . Steering | . Manufacturing Practices |
| . Finance | . Health |
| . Fire Safety | . Nominating |
| . Public Relations | |

The bylaws should include the concept of rotating Steering Committee members so as to provide continuity from year to year.

2. Health Committee

Mr. Nuechterlein referred to his letter of January 11 establishing a Health Subcommittee with Dr. Ted Torkelson of Dow acting as Chairman. Other members include:

- | | |
|---------------------|----------------------------|
| Dr. Maurice Johnson | - B. F. Goodrich |
| Dr. Hinderer | - Ethyl Corp |
| Mr. Mayo Smith | - Air Products & Chemicals |
| Mr. R. N. Wheeler | - Union Carbide |

Mr. Nuechterlein suggested that the Health Committee be requested to recommend what actions might be taken to clarify human health risks from vinyl chloride.

A compendium of Vinyl Chloride Toxicology Studies prepared by Dr. Torkelson was distributed for reference. (Copy attached).

3. Mr. Lawrence reviewed the plans for a visit of an EPA team to Dr. Maltoni on February 14. Request for U.S. industry representatives to be present has been made through John Stafford of ICI. (Note: This request was turned down by CEFIC at its meeting held on February 3).

REDACTED

SPI-10868

REDACTED

5. Mr. Savage reported on the action being taken in the New Jersey legislature to pass a bill that would prohibit manufacturing concerns to use any of 16 named carcinogens including vinyl chloride. Companies with direct involvement (B. F. Goodrich, Hooker, PPG, Shell and Tenneco), have met in Trenton and are working the New Jersey Chemical Industry Council to try to dis-involve vinyl chloride.

Because the passage of such a bill in New Jersey would have a direct effect on the industry's ability to manufacture or process PVC in New Jersey and likewise because it might lead to similar action in other states, Mr. Savage suggested that up to \$10,000 be allocated to support action on this concern. This request received a favorable vote by the Steering Committee.

Mr. Savage distributed a copy of the report on New Jersey activities prepared by Don White (copy attached).


6. Mr. Ferrante reported on the activities of the Communications Committee indicating that the media briefing have been halted temporarily because of the lack of specific positive information on the latest health issues. After discussion, it was agreed that the media briefings would continue even if it involves going without the doctor member of the briefing team. However, an attempt will be made to have the Health Committee develop interim responses to anticipated questions at its meeting to be held on February 17.

Copies of the latest PVC Management Summary being mailed to all member companies were also distributed.

7. Mr. Heckman reviewed the status of the FDA Regulation on PVC as is being covered in his regular reports. It is his opinion that FDA may soon be moving to finalize its position on this regulation.
8. Mr. Nuechterlein indicated that he would appoint a nominating committee to prepare a slate of nominations for a new Steering Committee and the positions called for in the proposed bylaws.

9. It was agreed that a final version of the proposed bylaws be circulated to the full membership of the Producers Group by March 22 and that the full Group should meet in Washington about mid-April.
10. The meeting adjourned at 3:30 P.M.

Respectfully submitted,


John R. Lawrence
Technical Director

Attachments

2/28/77

TOXICOLOGICAL STUDIES IN PROGRESS OR UNPUBLISHED

Principal Investigator - - - Source of Support	Route of Administration	Species	Dose Levels	Duration of Treatment	Nature of Study	Starting Date	Apparent Last Report	Anticipated Final Report	Tentative Conclusions To Date
L. Keplinger Industrial Bio Test Northbrook, Illinois - - - U.S. Chemical Co. through MCA	Inhalation	Rats Mice Hamsters	2500 200 & 50 ppm	6 hr/day for 9-12 months; held for life time	Carcino- genesis Lymphocyte transfor- mation	9/1973	5/1976 (Oral)	Overdue	Excess tumors in both sexes of all three species; mice more susceptible than rats; rats more than hamsters. Histopathology incomplete. No evidence of lymphocyte transformatio in rats at any dose.
Bingham University of Cincinnati - - - A/R. Tardiff -03-2148	Inhalation	Rats	6000, 600 ppm		Carcino- genesis; Teratogeni- sis; Trans- placental; Effect of Alcohol	5/1976	6/1976		Considerable pneumonia not related to exposure
Woodward Arsenal, MD - - - SC/R.M. Hehir	Inhalation	Rats, Mice	50,000 5000, 500 50 ppm	1 d to 20w	Acute and short term exposure for carcino- genesis	3/1976		Late 1978	
West Research - - - EHS/J.S. Woods I-ES-2-2084	Inhalation	Rats, Mice	1000, 250, 50 ppm		Carcino- genesis, serial sacrifice for histo- pathology		8/1976		Mice severely affected after 6-8 months
zelton - - - OSH									

SPI-10871

TOXICOLOGICAL STUDIES IN PROGRESS OR UNPUBLISHED

Principal Investigator Source of Support	Route of Administration	Species	Dose Levels	Duration of Treatment	Nature of Study	Starting Date	Apparent Last Report	Anticipated Final Report	Tentative Conclusions To Date
IVO, Netherlands European Companies through CEFIC	Inhalation	Rats	5000 ppm		Interim sacrifices for histopathology		8/1976		Considerable mortality after 44 weeks. Marked liver pathology with neoplastic nodules
	Ingestion	Rats	300 (gavage) 9, 3 & 1 mg/kg/day in PVC resin	84 weeks 90 weeks			10/1976		High mortality at 300 mg/kg day. Liver nodules at 3 mg/kg/day and higher
IRA, U.K.	Ingestion	Rats				In progress			
io Negri Institute						Only proposal available			

SPL-10873

EPIDEMIOLOGICAL STUDIES IN PROGRESS OR UNPUBLISHED

Name and/or Principle Investigator - - - Source of Support	Population Being Studied	Factors Being Studied	Final Report	Comments
Equitable Environmental Health (Formerly Taber-shaw-Cooper) - - - 31 U.S. Companies through MCA	10,183 male VCM production and polymerization employees	672 death certificates 1942-1972; estimated exposure, cumulative exposure, latency	1st quarter 1977	95% followup; overall SMR 89; vinyl chloride appear to be a weak, general carcinogen; lung cancer and "other and unspecified" appear elevated. Angiosarcomas of liver occur in most heavily exposed groups
Georgetown University; Organization Resources Counselors - - - Nine Plastic Manufacturers	Male and Female PVC Fabricators	4,592 death certificates 1964-1973; proportionate mortality	Feb., 1976	The proportionate mortality analysis used in this study do not permit calculation of rates. Pre-selection factors limit analysis to rare diseases, such as angiosarcomas which were not found in this population
Laval University - - -	Residents in Shawinigan, Quebec	Death certificates		Ten angiosarcomas in PVC employees. Study on area residents in progress.
Laval University - - -		Birth Records		In progress
George Wirth - - - OTS	Residents in New England	?		

MEDICAL STUDIES IN PROGRESS OR UNPUBLISHED

Name and/or Principle Investigator - - - Source of Support	Population Being Studied	Factors Being Studied	Final Report	
Dr. Carlos Tamburro University of Louisville - - - NCI and U.S. Industry (through MCA)	BFG Production Employees	Clinical Parameters Enzymes, Histology		

SPI-10875

